NeoChord Overview
- Year Founded
-
2007
- Status
-
Private
- Employees
-
18
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$13.6M
- Investors
-
6
NeoChord General Information
Description
Developer of an artificial chordae delivery system designed to resolve and restore normal mitral valve function. The company's system is used for conducting a minimally invasive procedure when the native chordae tendinae have become elongated or ruptured, while the heart is beating, and bypasses the need for conducting cardiopulmonary bypass or aortic cross-clamping, enabling surgeons to stop the leakage of blood backward through the mitral valve in patients suffering from mitral regurgitation.
Contact Information
Website
www.neochord.comCorporate Office
- 10900 73rd Avenue
- North Suite 101
- Maple Grove, MN 55369
- United States
Corporate Office
- 10900 73rd Avenue
- North Suite 101
- Maple Grove, MN 55369
- United States
NeoChord Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC | 13-Mar-2025 | $13.6M | Completed | Clinical Trials - General | ||
| 8. Secondary Transaction - Private | Completed | Clinical Trials - General | ||||
| 7. Later Stage VC (Series D) | 09-Feb-2021 | Completed | Clinical Trials - General | |||
| 6. Later Stage VC (Series C) | 08-Jun-2015 | Completed | Clinical Trials - General | |||
| 5. Debt - General | 25-Oct-2013 | Completed | Clinical Trials - General | |||
| 4. Later Stage VC (Series B2) | 19-Mar-2013 | Completed | Clinical Trials - General | |||
| 3. Early Stage VC (Series B) | 29-Jul-2011 | Completed | Startup | |||
| 2. Early Stage VC (Series A) | 07-Jul-2009 | $3.36M | $5.12M | Completed | Startup | |
| 1. Angel (individual) | 01-Jan-2007 | $1.76M | $1.76M | Completed | Startup |
NeoChord Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B2 | ||||||||
| Series B | 5,280,151 | $0.010000 | 8% | $1.04 | $1.04 | 1x | $0.12 | 3.51% |
| Series A | 9,317,473 | $0.010000 | 8% | $1.04 | $1.04 | 1x | $0.12 | 6.19% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
NeoChord Comparisons
Industry
Financing
Details
NeoChord Competitors (20)
One of NeoChord’s 20 competitors is Cardio Flow, a Venture Capital-Backed company based in Blaine, MN.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cardio Flow | Venture Capital-Backed | Blaine, MN | ||||
| Cardiac Dimensions | Venture Capital-Backed | Kirkland, WA | ||||
| Paragate Medical | Venture Capital-Backed | Haifa, Israel | ||||
| Pi-Cardia | Venture Capital-Backed | Rehovot, Israel | ||||
| CorWave | Venture Capital-Backed | Clichy, France |
NeoChord Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
NeoChord Patents
NeoChord Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230363908-A1 | Suture anchor for minimally invasive heart valve repair | Pending | 13-May-2022 | ||
| WO-2023220470-A1 | Suture anchor for minimally invasive heart valve repair | Inactive | 13-May-2022 | ||
| EP-4280972-A1 | Minimally invasive heart valve repair in a beating heart | Pending | 21-Jan-2021 | ||
| EP-4280972-A4 | Minimally invasive heart valve repair in a beating heart | Pending | 21-Jan-2021 | ||
| US-12496061-B2 | Minimally invasive heart valve repair in a beating heart | Active | 21-Jan-2021 | A61B17/0487 |
NeoChord Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
NeoChord Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Deerfield Capital | Lender/Debt Provider | Minority | ||
| Treo Ventures | Venture Capital | Minority | ||
| U.S. Venture Partners | Venture Capital | Minority | ||
| Andcor Companies | Corporation | Minority | ||
| Angel (individual) | Minority |
NeoChord FAQs
-
When was NeoChord founded?
NeoChord was founded in 2007.
-
Where is NeoChord headquartered?
NeoChord is headquartered in Maple Grove, MN.
-
What is the size of NeoChord?
NeoChord has 18 total employees.
-
What industry is NeoChord in?
NeoChord’s primary industry is Surgical Devices.
-
Is NeoChord a private or public company?
NeoChord is a Private company.
-
What is NeoChord’s current revenue?
The current revenue for NeoChord is .
-
How much funding has NeoChord raised over time?
NeoChord has raised $88.5M.
-
Who are NeoChord’s investors?
Deerfield Capital, Treo Ventures, U.S. Venture Partners, Andcor Companies, and are 5 of 6 investors who have invested in NeoChord.
-
Who are NeoChord’s competitors?
Cardio Flow, Cardiac Dimensions, Paragate Medical, Pi-Cardia, and CorWave are some of the 20 competitors of NeoChord.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
